Literature DB >> 8586468

Angiogenesis in malignant gliomas.

K H Plate1, W Risau.   

Abstract

One event that accompanies glioma progression is the upregulation of angiogenesis. Low-grade gliomas are moderately vascularized tumors whereas high-grade gliomas show prominent microvascular proliferations and areas of high vascular density. To analyze the molecular mechanisms underlying glioma angiogenesis, we studied the expression of vascular endothelial growth factor (VEGF) and its tyrosine kinase receptors VEGFR-1 and VEGFR-2 during normal brain development and glioma-induced angiogenesis. Our results suggest a paracrine control of angiogenesis and endothelial cell proliferation that is tightly regulated and transient in the embryonic brain, switched off in the normal adult brain, and turned on in tumor cells (VEGF) and the host vasculature (VEGFR-1 and -2) during tumor progression. It is unknown how VEGF and VEGF receptors are upregulated during glioma angiogenesis, but there is recent evidence that VEGF as well as endogenous inhibitors of angiogenesis could be under control of the tumor suppressor genes p53 and VHL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8586468     DOI: 10.1002/glia.440150313

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  85 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

Review 3.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

4.  The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

5.  Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease.

Authors:  Daniel Paris; Nowel Ganey; Magdalena Banasiak; Vincent Laporte; Nikunj Patel; Myles Mullan; Susan F Murphy; Gi-Taek Yee; Corbin Bachmeier; Christopher Ganey; David Beaulieu-Abdelahad; Venkatarajan S Mathura; Steven Brem; Michael Mullan
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

6.  ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.

Authors:  Maren Cam; Manish Charan; Alessandra M Welker; Piyush Dravid; Adam W Studebaker; Jeffrey R Leonard; Christopher R Pierson; Ichiro Nakano; Christine E Beattie; Eugene I Hwang; Madhuri Kambhampati; Javad Nazarian; Jonathan L Finlay; Hakan Cam
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

7.  Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades.

Authors:  Sabine Miebach; Stefan Grau; Vera Hummel; Peter Rieckmann; Joerg-Christian Tonn; Roland Helmut Goldbrunner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

8.  Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189.

Authors:  S Y Cheng; M Nagane; H S Huang; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

9.  Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

10.  Intratumoral hemorrhage-related differences in the expression of vascular endothelial growth factor, basic fibroblast growth factor and thioredoxin reductase 1 in human glioblastoma.

Authors:  Bulent Kaya; Onur Çiçek; Fatih Erdi; Siddika Findik; Yasar Karatas; Hasan Esen; Fatih Keskin; Erdal Kalkan
Journal:  Mol Clin Oncol       Date:  2016-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.